The pharmaceutical sector is complex and highly regulated in most economies. Intellectual property (IP) is a pharmaceutical and biopharmaceutical organizations most valuable resource, and its protection is a key to the company’s future success. Recent challenges over patents for varied newer drugs has emphasized that advancement is still required in balancing the opposing forces of innovation through protection of IP rights, versus the provision of affordable drugs for the emerging geographical regions across the globe. IP is the backbone to ensure development of new drugs. IP is extremely vital to improvise patient care, spurring economic growth and intensifying the innovation economy. In order to motivate researchers to explore new areas of medical innovation, modern IP systems and strong protections are crucial. The US pharmaceutical & biopharmaceutical industry drives the nation’s Research and Development (R&D) economy, thereby keeping the country at the forefront of advanced technology development. The pharma and Biopharma industry hence is a key generator of new IP’s across the globe. Intellectual Property (IP) is the backbone to ensure development of new treatments and cures. IP is extremely vital to improvise patient care, spurring economic growth and intensifying the innovation economy. In order to motivate researchers to explore new areas of medical innovation, modern IP systems and strong protections are crucial. The US pharmaceutical & biopharmaceutical industry drives the nation’s Research and Development (R&D) economy, thereby keeping the country at the forefront of advanced technology development. The pharma and Biopharma industry hence is a key generator of new IP’s across the globe.

With this overarching global theme of Ideate and Innovate, CPhI Conferences is pleased to present the, '9th Annual Pharma IPR Conference' scheduled on 4 - 6 March 2020 at Taj Santacruz, Mumbai.